Atugen Pens Target Validation Deal with AstraZeneca | GenomeWeb

NEW YORK, Oct. 16 – Atugen, a Berlin-based genomics company, said Tuesday it had signed a target validation deal with AstraZeneca.

Under the terms of the deal, Atugen will use its GeneBloc antisense technology to validate targets of interest to the British pharmaceutical company. The companies previously completed a target evaluation deal that dates back to 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.